Physician profile
Stacy B Brown
NPI 1093937872
$719,341.88
in general payments reported to CMS, 2019-2025
29 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83K · 2022: $185K · 2023: $151K · 2024: $166K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283K · Travel and Lodging: $157K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $282,833.01 |
| Travel and Lodging | $156,616.23 |
| Food and Beverage | $12,188.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $530,888.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $138,979.77 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $30,062.36 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $8,507.27 | 2021-2025 | |
| Esperion Therapeutics, INC. | $4,247.78 | 2021-2022 | |
| Corcept Therapeutics | $1,867.59 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $753.93 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $657.10 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $602.68 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $562.18 | 2021-2025 | Evenity, Repatha, Prolia |
| Insulet Corporation | $270.69 | 2021-2025 | Omnipod |
| Mannkind Corporation | $237.60 | 2022-2025 | Afrezza |
| Medtronic, INC. | $218.01 | 2024-2025 | Minimed 780g, Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.25 | 2021-2024 | Jardiance, Synjardy |
| Dexcom, INC. | $204.21 | 2023-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $193.74 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $170.47 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $155.64 | 2025 | Twiist |
| Zealand Pharma US, INC. | $123.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $102.87 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $85.89 | 2022 | |
| Cequr Corporation | $62.55 | 2023-2024 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $43.11 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $24.70 | 2024 | Arexvy, Trelegy Ellipta |
| Ibsa Pharma INC. | $22.57 | 2025 | Tirosint, Flector, Licart |
| Amneal Pharmaceuticals LLC | $22.24 | 2025 | Unithroid |
| Abbvie INC. | $16.30 | 2025 | |
| Evoke Pharma, INC. | $14.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.